ABSTRACT
Despite two years of intense global research activity, host genetic factors that predispose to a poorer prognosis and severe course of COVID-19 infection remain poorly understood. Here, we identified eight candidate protein mediators of COVID-19 outcomes by establishing a shared genetic architecture at protein-coding loci using large-scale human genetic studies. The transcription factor ELF5 (ELF5) showed robust and directionally consistent associations across different outcome definitions, including a >4-fold higher risk (odds ratio: 4.85; 95%-CI: 2.65-8.89; p-value<3.1×10−7) for severe COVID-19 per 1 s.d. higher genetically predicted plasma ELF5. We show that ELF5 is specifically expressed in epithelial cells of the respiratory system, such as secretory and alveolar type 2 cells, using single-cell RNA sequencing and immunohistochemistry. These cells are also likely targets of SARS-CoV-2 by colocalisation with key host factors, including ACE2 and TMPRSS2. We also observed a 25% reduced risk of severe COVID-19 per 1 s.d. higher genetically predicted plasma G-CSF, a finding corroborated by a clinical trial of recombinant human G-CSF in COVID-19 patients with lymphopenia reporting a lower number of patients developing critical illness and death. In summary, large-scale human genetic studies together with gene expression at single-cell resolution highlight ELF5 as a novel risk gene for COVID-19 prognosis, supporting a role of epithelial cells of the respiratory system in the adverse host response to SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Fenland Study (10.22025/2017.10.101.00001) is funded by the Medical Research Council (MC UU 12015/1). We further acknowledge support for genomics from the Medical Research Council (MC PC 13046). CL, EW, MP, and NJW are funded by the Medical Research Council (MC UU 00006/1 – Aetiology and Mechanisms). Non–COVID–19 autopsy samples were provided by the BrainBank/BioBank of the Department of Neuropathology at the Charite – Universitaetsmedizin Berlin, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany′s Excellence Strategy – EXC–2049 – 390688087. COVID–19 autopsies were supported by the the German Network University Medicine NUM FKZ 01KX2021 Organostrat and Defeat Pandemics (H.R. and F.L.H.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the local ethics committees (Berlin: EA1/144/13, EA2/066/20 and EA1/075/19) as well as by the Charite–BIH COVID–19 research board and was in compliance with the Declaration of Helsinki; autopsies were performed on the legal basis of paragraph 1 of the Autopsy Act of the state Berlin and paragraph 25(4) of the German Infection Protection Act.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics for protein levels are available from www.omicscience.org. Summary statistics for COVID–19 are available from https://www.covid19hg.org/results/r6/. scRNAseq data sets are available under the accession IDs: olfactory mucosa (GSE139522), nasopharynx (EGAS00001005461), and lungs (EGAS00001004689, EGAS00001004419, SAMEA6848756, SAMEA6848761, SAMEA6848765, SAMEA6848766).
